Atea Pharmaceuticals Q2 2024 GAAP EPS $(0.48) Beats $(0.77) Estimate
Benzinga Newsdesk 2 years ago
EarningsEarnings BeatsNews
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.77) by 37.66 percent.
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.77) by 37.66 percent.